Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgad554 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Zhinous Shahidzadeh Yazdi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Hauptthemen laut MEDLINE: Parathyroid Hormone, Vitamin D Deficiency. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Office of Dietary Supplements.
Abstract (Originalsprache)
Context
Canagliflozin has been reported to increase the risk of bone fracture—possibly mediated by decreasing 1,25-dihydroxyvitamin D (1,25(OH)2D) and increasing parathyroid hormone (PTH).
Objective
This work investigated whether baseline vitamin D (VitD) deficiency renders individuals vulnerable to this adverse effect and whether VitD3 supplementation is protective.
Methods
This community-based, outpatient study had a paired design comparing individual participants before and after VitD3 supplementation. Eleven VitD-deficient (25-hydroxyvitamin D [25(OH)D] ≤ 20 ng/mL) individuals were recruited from the Amish population in Lancaster, Pennsylvania. Participants underwent 2 canagliflozin challenge protocols (300 mg daily for 5 days): the first before and the second after VitD3 supplementation. In the VitD3 supplementation protocol, participants received VitD3 supplementation (50 000 IU once or twice a week depending on body mass index for 4-6 weeks) to achieve 25(OH)D of 30 ng/mL or greater. Two coprimary end points were identified: effects of VitD3 supplementation on canagliflozin-induced changes in 1,25(OH)2D and PTH. Secondary end points included effects of VitD3 supplementation on baseline levels of VitD metabolites and PTH.
Results
VitD3 supplementation increased mean 25(OH)D from 16.5 ± 1.6 to 44.3 ± 5.5 ng/mL (P = .0006) and 24,25-dihydroxyvitamin D (24,25(OH)2D) from 1.0 ± 0.1 to 4.3 ± 0.6 ng/mL (P = .0002). Mean 1,25(OH)2D and PTH were unchanged. VitD3 supplementation decreased the magnitude of canagliflozin-induced changes in 1,25(OH)2D (from −31.3%±4.7% to −9.3%±8.3%; P = .04) and PTH (from +36.2%±6.2% to +9.7%±3.7%; P = .005).
Conclusion
VitD deficiency rendered individuals more vulnerable to adverse effects of canagliflozin on biomarkers associated with bone health. VitD3 supplementation was protective against canagliflozin's short-term adverse effects on 1,25(OH)2D and PTH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
ORCID-Profile: Zhinous Shahidzadeh Yazdi, Simeon I Taylor
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institutes of Health Office of Dietary Supplements
Zitieren
APA
Shahidzadeh Yazdi, Z., Streeten, E. A., Whitlatch, H. B., Montasser, M. E., Beitelshees, A. L., & Taylor, S. I. (2024). Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad554
Vancouver
Shahidzadeh Yazdi Z, Streeten EA, Whitlatch HB, Montasser ME, Beitelshees AL, Taylor SI. Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad554
BibTeX
@article{ShahidzadehYazdi2024,
author = {Shahidzadeh Yazdi, Zhinous and Streeten, Elizabeth A and Whitlatch, Hilary B and Montasser, May E and Beitelshees, Amber L and Taylor, Simeon I},
title = {Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgad554}
}
EUVIMED